Blue light used to harden tooth fillings stunts tu...(therapy may serve as an adjunct to conve...)
Navigation Links
Blue light used to harden tooth fillings stunts tumor growth
Date:6/24/2008
therapy may serve as an adjunct to conventional cancer therapy. Patients may, therefore, receive lower doses of chemotherapy, which would decrease the adverse effects most cancer patients experience from standard chemotherapy regimens."
'/>"/>
| Contact: Amy Connell aconnell@mcg.edu 706-721-8605 Medical College of Georgia Source:Eurekalert |
Related biology news :
1. July 2008 GEOLOGY and GSA Today media highlights
2. July 2008 highlights
3. Genome sequence of small marine creature sheds light on vertebrate origins
4. Highlights from the June 2008 Journal of the American Dietetic Association
5. New text highlights role of microorganisms in alternative energy development
6. June GEOSPHERE media highlights
7. Undergraduates develop dirt-powered microbial fuel cells to light Africa
8. UV lotion lights the way to cleaner facilities
9. Highlights from the May 2008 Journal of the American Dietetic Association
10. European light research opens door for optical storage and computing
11. Detecting dangerous chemicals with lasers, exploring the brains circuitry with light and more
Post Your Comments:
Related Image:
 Blue light used to harden tooth fillings stunts tumor growth |
Breaking Biology News(10 mins):New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3Type 2 diabetes gene predisposes children to obesity 2Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2White House Launches Fishy Expedition 53881 1White House Launches Fishy Expedition 53881 2Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 1Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 2Care to Care Receives Full URAC Health Utilization Management Accreditation 53880 3NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 1NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 2NBCH Calls for Cost Containment and System Transformation in Health Care Reform Legislation 53878 3
Other Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New vaccine may give long-term defense against deadly bird flu and its variant forms 2New vaccine may give long-term defense against deadly bird flu and its variant forms 3New vaccine may give long-term defense against deadly bird flu and its variant forms 4Researchers uncover details about how dietary restriction slows down aging 2Researchers uncover details about how dietary restriction slows down aging 3
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4
[0] Lyric Presents the Sounds of the Season[0] Super cool atom thermometer[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |